Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry
- PMID: 34034985
- DOI: 10.1016/j.jcf.2021.05.003
Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry
Abstract
Background: Epidemiology and potential risk factors for cystic fibrosis arthropathy (CFA) were studied in a relevant cystic fibrosis (CF) patient cohort.
Methods: Cohort study of patients included in the German CF registry in 2016-2017. Descriptive analysis, exploratory tests and multivariable logistic regression were used to assess prevalence of CFA and associated potential risk factors for adult patients with/without chronic Pseudomonas aeruginosa infection.
Results: 6069 CF patients aged from 0 to 78 years were analysed. CFA was observed in 4.9% of the patients. Prevalence was significantly higher in adult patients (8.4%) compared to patients <18 years (0.7%; p<0.0001). Logistic regression analyses in adult patients (n=3319) showed that CFA was significantly associated with increasing age (OR=1.04; 95% CI: 1.02-1.05; p<0.0001), female gender (OR=2.10; 95%CI:1.52-2.90; p<0.0001), number of hospitalizations (OR=1.24; 95%CI:1.12-1.36; p<0.0001), chronic P. aeruginosa infection (OR=1.83; 95%CI:1.28-2.61; p=0.0009), CF-related diabetes (OR=1.69; 95%CI:1.23-2.33; p=0.0013), pancreatic insufficiency (OR=2.39; 95%CI:1.28-4.46; p=0.0060) and sinusitis/polyps (OR=1.91; 95%CI:1.39-2.62; p<0.0001). In a subgroup analysis of adults without chronic P. aeruginosa infection (n=1550) CFA was also significantly associated with increasing age, female gender, increasing number of hospitalizations, pancreatic insufficiency as well as sinusitis/polyps; antimycotic treatment associated only in this subgroup while association with CF-related diabetes was not significant.
Conclusion: CFA is a frequent and clinically relevant co-morbidity particularly in adult CF patients. CFA is significantly more common in patients with chronic P. aeruginosa colonization but associations with other indicators for a more severe disease course were identified regardless of P. aeruginosa colonization status.
Keywords: Aspergillus fumigatus; Cystic fibrosis; Pseudomonas aeruginosa; arthropathy; epidemiology; gender.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of conflict of interest The authors have no conflict of interest related to this manuscript.
Similar articles
-
The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.Dev Period Med. 2015 Jan-Mar;19(1):66-79. Dev Period Med. 2015. PMID: 26003072
-
Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function.Sci Rep. 2020 Nov 4;10(1):18999. doi: 10.1038/s41598-020-75886-w. Sci Rep. 2020. PMID: 33149181 Free PMC article.
-
Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.Eur Respir J. 2014 Jan;43(1):125-33. doi: 10.1183/09031936.00166412. Epub 2013 Apr 18. Eur Respir J. 2014. PMID: 23598952
-
The co-colonization prevalence of Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis: A systematic review and meta-analysis.Microb Pathog. 2018 Dec;125:122-128. doi: 10.1016/j.micpath.2018.09.010. Epub 2018 Sep 11. Microb Pathog. 2018. PMID: 30217514
-
Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges: Adult Cystic Fibrosis Series.Chest. 2022 Feb;161(2):356-364. doi: 10.1016/j.chest.2021.09.003. Epub 2021 Sep 15. Chest. 2022. PMID: 34536383 Review.
Cited by
-
Prevalence and Impact of Rheumatologic Pain in Cystic Fibrosis Adult Patients.Front Med (Lausanne). 2022 Feb 8;8:804892. doi: 10.3389/fmed.2021.804892. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35211488 Free PMC article.
-
First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in Romania.Diagnostics (Basel). 2022 Jan 7;12(1):137. doi: 10.3390/diagnostics12010137. Diagnostics (Basel). 2022. PMID: 35054306 Free PMC article.
-
Success of the German Cystic Fibrosis Registry.Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70076. doi: 10.1002/pds.70076. Pharmacoepidemiol Drug Saf. 2025. PMID: 39775994 Free PMC article.
-
The ageing of people living with cystic fibrosis: what to expect now?Eur Respir Rev. 2024 Oct 30;33(174):240071. doi: 10.1183/16000617.0071-2024. Print 2024 Oct. Eur Respir Rev. 2024. PMID: 39477350 Free PMC article. Review.
-
The Changing Face of Cystic Fibrosis and Its Implications for Screening.Int J Neonatal Screen. 2020 Jul 3;6(3):54. doi: 10.3390/ijns6030054. eCollection 2020 Sep. Int J Neonatal Screen. 2020. PMID: 33123635 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical